Healthcare Equipment and Supplies
Company Overview of AxoGen, Inc.
AxoGen, Inc. operates as a medical technology company. It offers a portfolio of nerve repair solutions for various surgical peripheral nerve repair needs. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf human nerve allograft for bridging nerve discontinuities without the comorbidities associated with another surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue atta...
13631 Progress Boulevard
Alachua, FL 32615
Key Executives for AxoGen, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $511.0K
Senior Vice President of Business Development, General Counsel and Director
Total Annual Compensation: $303.0K
Senior Vice President of Sales
Total Annual Compensation: $374.3K
Compensation as of Fiscal Year 2015.
AxoGen, Inc. Key Developments
AxoGen, Inc. Presents at The Leerink Partners 6th Annual Global Healthcare Conference, Feb-15-2017 01:30 PM
Jan 24 17
AxoGen, Inc. Presents at The Leerink Partners 6th Annual Global Healthcare Conference, Feb-15-2017 01:30 PM. Venue: Lotte New York Palace, 455 Madison Ave., New York, New York, United States.
AxoGen, Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2016; Reiterates 2017 Annual Revenue
Jan 9 17
AxoGen, Inc. provided preliminary unaudited earnings guidance for the fourth quarter and full year ended December 31, 2016. Fourth quarter revenue is expected to be at least $11.3 million, up 45% compared to the fourth quarter of 2015 revenue of $7.8 million.
Full year 2016 revenue is expected to be at least $41.0 million, up 50% compared to 2015 revenue of $27.3 million. Management increases its full year 2016 revenue guidance to at least $41.0 million from its previous estimate of over $40.0 million. Management reiterates its full year 2016 gross margin guidance to exceed 80%.
Management reiterates 2017 annual revenue will grow at least 40% over 2016 revenue and gross margins will remain above 80%.
AxoGen, Inc. Appoints Ivica (Ivan) Ducic as Medical Director of Clinical and Translational Sciences
Jan 5 17
AxoGen, Inc. announced the appointment of Ivica (Ivan) Ducic, M.D., Ph.D. as Medical Director of Clinical and Translational Sciences. Dr. Ducic will be responsible for AxoGen's global medical affairs programs as a non-officer member of the leadership team. Dr. Ducic is the past president of American Society for Peripheral Nerve.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|